Terry Moran, ABC news correspondent, shares his personal story of facing Alzheimerās and getting his DNA tested for the disease. This segment also features Cure Alzheimerās Fund Research Consortium member Dr. Sam Gandy participating in an upcoming GQ article spotlighting ārock-starā Alzheimerās scientists photographed with real rock stars including Sheryl ...
March 26, 2009
As our research ābenchā continues to grow, weāre thrilled to welcome two new Research Consortium and two new Scientific Advisory Board members to our team. Each member brings unique expertise to accelerate our progress toward a cure. Bruce Lamb, Ph.D., of the Cleveland Clinicās Department of Neurosciences, is the newest addition ...
October 16, 2015
It is known that high cholesterol is associated with cardiovascular disease. Cholesterol also regulates the production of the toxic amyloid beta (AĪ²) peptide in Alzheimerās disease (AD). Therapies already developed or in development for dyslipidemia and atherosclerosis are becoming attractive for reducing AĪ² in the brains of patients affected by ...
February 12, 2011
When Charline Kim of Los Angeles turned 27 on Feb. 28, 2014, she asked her friends to make a donation to Cure Alzheimerās Fund to support her grandma, who has the disease. Charline even donated $100 as a birthday present to herself. āI love my grandma and she is one ...
April 10, 2014
Alzheimer’s disease (AD) is characterized by two hallmark pathologies. The first is accumulation of amyloid-beta peptide (Abeta) outside neurons as insoluble amyloid plaques. The second is aggregation inside of neurons of tau protein as filamentous structures called neurofibrillary tangles. High amyloid loads in brain induce tauopathy and amyloid/tauopathy together appear ...
January 11, 2016
Many lines of evidence suggest that beta-amyloid peptides cause neuronal damage and affect fundamental memory processes early in the course of Alzheimer’s disease (AD). Two membrane-associated enzymes, namely betasecretase (BACEl) and gamma-secretase are responsible for beta-amyloid production. Understanding the details regarding the cellular and molecular mechanisms involved in beta-amyloid production ...
December 6, 2012
There is general agreement that beta amyloid (AĪ²) is a likely causative agent in theĀ development of Alzheimerās disease. There is growing evidence that early in the disease anĀ important target of AĪ² is the synapse, the site of communication between neurons. We haveĀ found that exposure of synapses to AĪ² causes their ...
January 18, 2013
Large, poorly soluble aggregates of the amyloid-beta peptide form the senile plaques that are a pathological hallmark of Alzheimerās disease, but the extent of plaque deposition correlates only moderately with dementia; for example many middle aged and elderly people have extensive plaque deposition without any signs of dementia. Instead, several ...
December 10, 2013
PICALM, the gene encoding phosphatidylinositol binding clathrin assembly (PICALM) protein, plays a key role in endocytosis, a process which regulates the function of cell receptors and synaptic transmission. Several GWAS studies of AD have replicated the association of PICALM with AD and shown relationships with neurodegenerative processes underlying disease. Additionally, ...
July 17, 2014
The proposed grant will assist in the purchase of an Orbitrap Fusion Tribrid Mass Spectrometer system toĀ enable the development of a method to assess tau production and clearance rates in humans, animal models,Ā and in vitro experiments. This cutting edge mass spectrometer system will provide more precise measurementsĀ with the ultra-low abundance ...
August 7, 2014
